Xenetic Biosciences (XBIO)
NASDAQ:XBIO
Want to see XBIO full AI Analyst Report?
Top Page
Xenetic Biosciences
(NASDAQ:XBIO)
Select Model
Select Model
Rating:51Neutral
Price Target:
$3.00
▲(35.75% Upside)
Action:ReiteratedDate:04/25/26
XBIO’s score is held back primarily by weak fundamentals—ongoing net losses and sustained cash burn despite improving revenue momentum—while the low-debt balance sheet reduces financial stress. Technicals are a relative positive with the stock trading above major moving averages and positive MACD, but valuation support is limited given the negative P/E and lack of dividend.
Positive Factors
Debt-light Balance Sheet
A near-zero debt position materially reduces refinancing and interest-rate risk, giving management optionality to fund R&D via equity, partnerships, or non-debt instruments. Over 2–6 months a debt-light capital structure lowers solvency risk and preserves flexibility for strategic choices.
Negative Factors
Persistent Negative Cash Flow
Consistent negative operating and free cash flow means the company cannot self-fund operations and remains dependent on external financing. Over a 2–6 month horizon this structural cash burn creates funding risk and can force dilutive financings or restrict R&D/program timelines if market access tightens.
Read all positive and negative factors
Positive Factors
Negative Factors
Debt-light Balance Sheet
A near-zero debt position materially reduces refinancing and interest-rate risk, giving management optionality to fund R&D via equity, partnerships, or non-debt instruments. Over 2–6 months a debt-light capital structure lowers solvency risk and preserves flexibility for strategic choices.
Read all positive factors
Xenetic Biosciences (XBIO) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$7.15M
Dividend YieldN/A
Average Volume (3M)1.70M
Price to Earnings (P/E)―
Beta (1Y)0.38
Revenue Growth19.04%
EPS Growth37.12%
CountryUS
Employees2
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.62
Shares Outstanding2,291,056
10 Day Avg. Volume5,053,508
30 Day Avg. Volume1,695,238
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)0.50
Price to Sales (P/S)1.24
P/FCF Ratio-1.61
Enterprise Value/Market Cap-0.36
Enterprise Value/Revenue-0.86
Enterprise Value/Gross Profit-0.86
Enterprise Value/Ebitda0.92
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-3.32
Revenue Forecast (FY)$3.00M
Xenetic Biosciences Business Overview & Revenue Model
Company Description
Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing XCART, a personalized chimeric antigen receptor T cell (CAR T) platform technology engineered to target patient-specific tumor neoantigens. The company engages in the dis...
How the Company Makes Money
null...
Xenetic Biosciences Financial Statement Overview
Summary
Income Statement
22
Negative
Balance Sheet
64
Positive
Cash Flow
28
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 2.98M | 2.50M | 2.54M | 1.71M | 1.16M |
| Gross Profit | 2.98M | 2.50M | 2.54M | 1.71M | 1.16M |
| EBITDA | -2.83M | -4.05M | -4.52M | -6.69M | -5.71M |
| Net Income | -2.68M | -3.96M | -4.13M | -6.55M | -5.65M |
Balance Sheet | |||||
| Total Assets | 8.36M | 6.90M | 10.61M | 14.72M | 19.82M |
| Cash, Cash Equivalents and Short-Term Investments | 7.88M | 6.17M | 8.98M | 13.10M | 18.24M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 27.04K |
| Total Liabilities | 968.02K | 894.26K | 809.59K | 1.07M | 1.42M |
| Stockholders Equity | 7.40M | 6.01M | 9.80M | 13.65M | 18.39M |
Cash Flow | |||||
| Free Cash Flow | -2.29M | -2.82M | -4.11M | -5.15M | -4.74M |
| Operating Cash Flow | -2.29M | -2.82M | -4.11M | -4.65M | -4.74M |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | -500.00K | 0.00 |
| Financing Cash Flow | 4.00M | 0.00 | 0.00 | 0.00 | 11.45M |
Xenetic Biosciences Technical Analysis
Positive
2.21
Price Trends
2.70
Positive
2.52
Positive
2.99
Positive
Market Momentum
0.19
Negative
67.13
Neutral
86.88
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For XBIO, the sentiment is Positive. The current price of 2.21 is below the 20-day moving average (MA) of 3.08, below the 50-day MA of 2.70, and below the 200-day MA of 2.99, indicating a bullish trend. The MACD of 0.19 indicates Negative momentum. The RSI at 67.13 is Neutral, neither overbought nor oversold. The STOCH value of 86.88 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for XBIO.
Xenetic Biosciences Risk Analysis
Xenetic Biosciences disclosed 67 risk factors in its most recent earnings report. Xenetic Biosciences reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Xenetic Biosciences Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $7.15M | -2.15 | -60.33% | ― | 19.04% | 37.12% | |
49 Neutral | $10.91M | -0.67 | -87.05% | ― | -80.98% | 16.94% | |
48 Neutral | $22.44M | -1.28 | -74.15% | ― | 13.77% | 30.30% | |
44 Neutral | $2.16M | 0.71 | 400.16% | ― | -97.89% | 62.56% |
* Healthcare Sector Average
XBIO
Xenetic Biosciences
3.12
-0.03
-0.95%
ERNA
Eterna Therapeutics
7.82
-67.14
-89.57%
VYNE
VYNE Therapeutics
0.67
-0.63
-48.23%
APRE
Aprea Therapeutics
0.88
-0.77
-46.76%
HCWB
HCW Biologics
0.32
-6.83
-95.52%
Xenetic Biosciences Corporate Events
Executive/Board Changes
Xenetic Biosciences Grants Equity Award to Interim CEO
Positive
Apr 24, 2026
On April 21, 2026, Xenetic Biosciences, Inc. granted Interim Chief Executive Officer and Chief Financial Officer James Parslow an award of 100,000 shares of restricted stock under its Amended and Restated Equity Incentive Plan. Of these shares, 7,...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.